Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Prior mis-management did a lot of harm to Advaxis. The company is slowly getting on the right path once again though and market sentiment will soon follow. News of Orphan Drug Designation for head and neck is another advancement.
Getting Mayes on board will prove to be a good move for Advaxis as they move forward. His experience in the healthcare field, more specifically oncology, should be reassuring for shareholders who have doubts about Advaxis. Personal involvement in the company shows that Mayes believes in the technology and its potential.
O'Connor continues to build for the future. Share price, though lagging, will follow. Another move that further validates Advaxis.
Advaxis is a development stage biotech with no revenues. As per their management (take a look at latest company presentation on their site), the company is in talks to finalize definitive agreements.
One is to license ADXS-HPV for commercialization in Asia (except India) with Yenson. The other is licensing deal with animal health division of major pharmaceutical company for ADXS-cHER2. These have the potential to bring in some funding.
Upside and downside really depend on the outcomes of several upcoming catalysts. Comparing them to others in the field like INO ($400M cap) and IMUC ($150M), you see how undervalued Advaxis is with a sub $50M cap
Not much we can do about that. Looking forward to news out of SITC meeting in early November where Phase II data will be presented. That should be a nice driver of growth, assuming data is as expected.
http://www.sitcancer.org/2013
With financial stability and pressures of being taken off OTC, management can focus on daily operations to advance the company. Such news releases should be appearing more frequently now, especially with upcoming catalysts
Positive news as company is further developing their shock wave applications.
http://finance.yahoo.com/news/sanuwave-receives-u-patent-type-123000840.html
Not too sure of timing but the company has several catalysts before 2014 that have the potential to rally price. Check the recent seeking alpha pieces that go into further detail about upcoming catalysts.
Short term pain for long term gain
Total proceeds of $23 mill, including the warrants. This should give Advaxis enough to fund operations for foreseeable future. Will begin trading on NASDAQ CM tomorrow. Good news for Advaxis outlook as now financials will be supportive of the science. So far, O'Connor has delivered. Partnership next up on the to Do list
Recent 8K to issue Iliad shares in place of the cancelled warrants is a move focused on longer term future of company. With the potential raising of ~$15 mill in sight, Advaxis is well positioned to continue driving the upward momentum to something more than a temporary spike in SP.
Gas tank is full with catalysts like uplisting, partnership and Orphan designations. Most of these are dependent on one another, starting with uplisting and raising. IMO these are primary influences of momentum for at least next quarter.
I would assume some investors are waiting on the sidelines until "dilution" is announced. On that news, they will be looking to move in and add further buying demand.
Imminent Uplisting to NASDAQ
http://seekingalpha.com/article/1734972-advaxis-s-1-filing-foreshadows-imminent-uplisting-to-nasdaq
Very informative article released on SA talking about future of ADXS and potential uplisting.
The S-1 filing (Sept 27th) announced company has applied to uplist shares on NASDAQ. However, before that can happen ADXS needs shareholder equity of at least $5million to meet the requirement. To reach this, ADXS would need to raise approx $12 mill.
This "dilution" is a necessary move to advance the company forward. Assuming ADXS is uplisted, liquidity and the validation of being on the NASDAQ will give the company leverage in any partnership negotiations.
Investors waiting on positive PR news. Raising, uplist, FDA's decision on oprhan status, partnership talks. The catalysts are lined up for this to take off. Chaos in markets, but ADXS seeing some good buying today.
If one event is announced, I think the others will follow in a domino effect. Exiting times ahead
Unwarranted selling could end up being a good buying opportunity. So far today, it's down 8% on positive news that company is on schedule with their enrollment for supplemental clinical trial. Keep in mind, volume is below average
Sanuwave remains on schedule to complete enrollment by early 2014. Recent releases have all been positive, the price will indicate this soon enough.
Barry Jenkins CFO buys 10k in open market purchase.
Surprised this didn't hit the wire but purchasing 13,500 shares @ $0.74 is a strong signal CFO is sending.
http://yahoo.brand.edgar-online.com/displayfilinginfo.aspx?FilingID=9516229-1209-9090&type=sect&TabIndex=2&companyid=765132&ppu=%252fdefault.aspx%253fcik%253d1417663
Looking good with the recent price appreciation on stronger volume. Also, GLSO is up on www.stockcharts.com. Thanks to those who requested for the ticker.
http://stockcharts.com/h-sc/ui?s=glso
Lets increase exposure and get the ticker listed on StockCharts.com before GlassesOff tackles the mass market of those with glasses.
Please request stock chart here -> http://stockcharts.com/support/symbolrequest.html
Thank you
Further information is a good sign. Still under review. Patience will pay off
I double that BB. O'Connor's prior experience should give investors plenty of hope.
His involvement with positioning ImClone for a $6.5 billion takeover by Eli Lilly in 2008, after the whole trading scandal, speaks volumes. In addition to that, he helped build PharmaNet into a leading CRO. With him running the show, Advaxis mis-management should not be a concern going forward.
It would be foolish to short this. The recent run-up to $11 cannot be justified as there has not been any significant news released. With that said however, upcoming catalyst (partnerships, possible uplist, Orphan application under review) and its low float can easily burn any short.
The appointment of O'Connor has brought life back to the company. Mis-management will not be an issue that spirals this down again. There will great volatility swings, like we've seen recently, but in the longer term, I believe the trend will be bullish.
Excited to see some form of publicity up online. Once the app is launched for iOS, I'd expect more advertising
It closed with a price of $1.00, so in comparison to what participants in private placement paid, stock trading at quite a discount.
Your frustration is warranted rmarc, management has been incompetent. Advaxis` science is credible, however they are still early in clinical stages. As much as I`d love for funding sources to be knocking on our door, an orphan drug candidate (not even granted approval) in Phase II trials isn`t going to have many bidders. Just not sexy enough. It`s management job to go out and sell the story in exchange for legitimate financing. This is where I feel Moore failed us. This is also why I have hope in Dan O`Connor. If his past experience is any indication, the man can sell.
The SeekingAlpha article generated some positive publicity, no doubt. The move up, however, has also been supported by strong volume these last two days. 100k! I don't know if a Seeking Alpha article can have that sort of pull
With recent turnaround in momentum, in conjunction with Orphan status granted and newly appointed Dan O'Connor, investors may be looking to average down, thus leading to a further spike in price.